Literature DB >> 16049202

Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users.

Stephanie R Bialek1, William A Bower, Karen Mottram, Dave Purchase, T Nakano, Omana Nainan, Ian T Williams, Beth P Bell.   

Abstract

During January-April, 2000, 12 cases of acute hepatitis B were reported in Pierce County, Washington, compared with seven in all of 1999. Seven (58.3%) case patients were injection drug users (IDUs), three of whom were coinfected with hepatitis D virus (HDV) and died of fulminant hepatitis. Vaccination clinics were implemented at the local health department and needle exchange program to control the outbreak. We investigated this outbreak to determine risk factors for hepatitis B virus (HBV) transmission among IDUs. Hepatitis B cases were ascertained through routine surveillance and prevaccination testing at vaccination clinics. We conducted a case-control study comparing IDU case patients with HBV-susceptible IDUs identified at the vaccination clinics. Fifty-eight case patients were identified during January-December, 2000, 20 (34.5%) of whom were coinfected with HDV. Thirty-eight case patients (65.5%) reported current IDU. In the case-control study, the 17 case patients were more likely than the 141 controls to report having more than one sex partner [odds ratio (OR) =4.8, 95% confidence interval (CI) =1.5-15.0], injecting more than four times a day (OR = 4.5, 95% CI =1.2-15.6) and sharing drug cookers with more than two people (58.8% vs. 14.0%, OR =14.0, 95% CI =2.4-81.5). Results were similar after controlling for syringe sharing in multivariable analysis. IDUs should be vaccinated against hepatitis B and should be advised against sharing drug injection equipment.

Entities:  

Mesh:

Year:  2005        PMID: 16049202      PMCID: PMC3456050          DOI: 10.1093/jurban/jti094

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  32 in total

1.  HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1.

Authors:  M C Clatts; R Heimer; N Abdala; L A Goldsamt; J L Sotheran; K T Anderson; T M Gallo; L D Hoffer; P A Luciano; T Kyriakides
Journal:  J Acquir Immune Defic Syndr       Date:  1999-10-01       Impact factor: 3.731

2.  Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water.

Authors:  C B McCoy; L R Metsch; D D Chitwood; P Shapshak; S T Comerford
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

3.  Reductions in high-risk drug use behaviors among participants in the Baltimore needle exchange program.

Authors:  D Vlahov; B Junge; R Brookmeyer; S Cohn; E Riley; H Armenian; P Beilenson
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-12-15

4.  Sequence-specific, single-primer amplification and detection of PCR products for identification of hepatitis viruses.

Authors:  O V Nainan; T L Cromeans; H S Margolis
Journal:  J Virol Methods       Date:  1996-09       Impact factor: 2.014

5.  Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program.

Authors:  A S Månsson; T Moestrup; E Nordenfelt; A Widell
Journal:  Scand J Infect Dis       Date:  2000

6.  Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995.

Authors:  N Crofts; C K Aitken
Journal:  Med J Aust       Date:  1997-07-07       Impact factor: 7.738

7.  Hepatitis B outbreak at Glenochil prison during January to June 1993.

Authors:  S J Hutchinson; D J Goldberg; S M Gore; S Cameron; J McGregor; J McMenamin; J McGavigan
Journal:  Epidemiol Infect       Date:  1998-08       Impact factor: 2.451

8.  Syringe exchange and risk of infection with hepatitis B and C viruses.

Authors:  H Hagan; J P McGough; H Thiede; N S Weiss; S Hopkins; E R Alexander
Journal:  Am J Epidemiol       Date:  1999-02-01       Impact factor: 4.897

9.  Hepatitis in used syringes: the limits of sensitivity of techniques to detect hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA, and antibodies to HBV core and HCV antigens.

Authors:  R Heimer; K Khoshnood; B Jariwala-Freeman; B Duncan; Y Harima
Journal:  J Infect Dis       Date:  1996-04       Impact factor: 5.226

10.  Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report.

Authors:  S M Shah; P Shapshak; J E Rivers; R V Stewart; N L Weatherby; K Q Xin; J B Page; D D Chitwood; D C Mash; D Vlahov; C B McCoy
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-03-01
View more
  6 in total

Review 1.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

2.  Prevalence and correlates of syphilis and condom use among male injection drug users in four Afghan cities.

Authors:  Catherine S Todd; Abdul Nasir; Mohammad Raza Stanekzai; Abdullah M S Abed; Steffanie A Strathdee; Christian T Bautista; Paul T Scott; Boulos A Botros; Jeffrey Tjaden
Journal:  Sex Transm Dis       Date:  2010-11       Impact factor: 2.830

Review 3.  Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Mariantonietta Pisaturo; Margherita Macera; Nicola Coppola
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

4.  Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011-2013.

Authors:  C Brouard; J Pillonel; P Sogni; A Chollet; J V Lazarus; X Pascal; F Barin; M Jauffret-Roustide
Journal:  Epidemiol Infect       Date:  2017-01-19       Impact factor: 4.434

5.  The prevalence of isolated hepatitis B core antibody and its related risk factors among male injected drug users in Isfahan prisons.

Authors:  Kiana Shirani; Zary Nokhodian; Nazila Kassaian; Peyman Adibi; Alireza Emami Naeini; Behrooz Ataei
Journal:  Adv Biomed Res       Date:  2015-01-30

6.  Hepatitis D Virus Infection Among Hepatitis B Surface Antigen Carriers and in "Isolated anti-HBc" Antibodies Profile in Central Tunisia.

Authors:  Salma Mhalla; Yosr Kadri; Sana Alibi; Amel Letaief; Jalel Boukadida; Naila Hannachi
Journal:  Hepat Mon       Date:  2016-01-16       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.